Lilly moves to bolster its oncology pipeline
Eli Lilly's cancer research slate includes two new collaborations.
The first is a three-year collaboration with the Dana-Farber Cancer Institute in which the Harvard-affiliated organization will work with the drugmaker on preclinical studies and clinical trial designs for unspecified pipeline treatments. Lilly said in a statement that it will retain ownership of the compounds and did not disclose the financial terms of the deal.
The drug manufacturer also entered a collaboration agreement with the Sarah Cannon Research Institute to develop LY3023414, an investigational cancer compound. Lilly is exploring the compound's use for cancers including non-small cell lung cancer, breast cancer and non-Hodgkin's lymphoma. SCRI is the research division of the Hospital Corporation of America's cancer division called Sarah Cannon. SCRI participates in about 500 clinical trials a year and will help design and manage Lilly's LY3023414 clinical trials. Lilly declined to comment on the duration of the agreement or the financial terms.
Although known for diabetes, Lilly's portfolio includes the non-small cell lung and gastric cancer drug Cyramza, erectile dysfunction drug Cialis and ADHD medication Strattera. Pipeline drugs include the Phase-III Alzheimer's medication solanezumab and Phase-III rheumatoid arthritis drug baricitinib.